Elanco Vira Shield 6 + L5 HB Vaccine 250 mL/50 Dose

Elanco Vira Shield 6 + L5 HB Vaccine 250 mL/50 Dose

For use in healthy cattle, including pregnant cows and heifers, as an aid in the prevention of disease caused by infectious bovine rhinotracheitis (IBR), bovine virus diarrhea (BVD Type 1 and BVD Type 2), parainfluenza Type 3 (PI₃), and bovine respiratory syncytial (BRSV) viruses and Leptospira canicola, grippotyphosa, hardjo-bovis, icterohaemorrhagiae, and pomona. For use in calves vaccinated at four weeks of age, or older, as an aid in the prevention of hardjo-bovis kidney colonization, and as an aid in preventing urinary shedding and reproductive tract infection for 12 months. Produced from non-cytopathic (BVD Type 1 and BVD Type 2) and cytopathic (BVD Type 1) isolates. Vaccinated animals subsequently exposed to L. borgpetersenii serovar hardjo (type hardjo-bovis) have been shown to clear renal infections within 8 weeks of exposure

Features:

Vira Shield leads the way in providing a complete line of flexible, safe, and powerful inactivated vaccines that protect against up to 13 respiratory, reproductive and leptospirosis diseases.

Easy to implement in any management program or whole-herd protocol, Vira Shield 6 combinations can be used in pregnant cows, heifers and calves nursing pregnant cows. Vira Shield has been shown to protect against infectious bovine rhinotracheitis (IBR) abortion eight months post vaccination.1

Unlike vaccines that carry label restrictions and products that require cows to be vaccinated prior to breeding, Vira Shield is easy to implement into any management program or whole-herd protocol.1 State-of-the-art adjuvant Xtend® SP prolongs stimulation of the immune system.2 Vira Shield delivers broad-spectrum, field-proven protection against the most devastating diseases.

• Safe for use on all cattle, even pregnant cows and calves nursing pregnant cows
• 12-month duration of immunity label claim for Lepto hardjo-bovis, the most common cause of leptospirosis in the US3
• The only inactivated vaccine to feature 3-way BVD coverage including cytopathic (CP) Type 1, noncytopathic (NCP) Type 1 and Type 2
• Demonstrated to protect against IBR abortion eight months post vaccination
• Provides both humoral and cell-mediated immunity4
• Powerful, long-lasting control with state-of-the-art adjuvant, Xtend® SP